S-P licenses Toyama Phase III antibiotic
Executive Summary
Schering-Plough's Schering Corp. has signed a letter of intent to acquire an exclusive worldwide development and marketing license to Toyama Chemical Co.'s Phase III quinolone antibiotic garenoxacin (T-3811). Toyoma will retain rights in Japan, Korea, and China.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice